

**Brightlabs BV**

Villafioraweg 1, 5928 SZ Venlo, The Netherlands

Tel.: 077-7703374

[info@brightlabs.nl](mailto:info@brightlabs.nl)

Report number:

CoA-

2021-5058

Report date:

27 January 2022

**Analytical report**

|                 |                        |                 |                                    |
|-----------------|------------------------|-----------------|------------------------------------|
| <b>Client:</b>  | Cibdol                 | <b>Contact:</b> | Inge van Delft /<br>Celeste Smeets |
| <b>Address:</b> | Handelsweg 1a, 5492 NL | <b>City:</b>    | St. Oedenrode                      |

|                                |                  |                                               |                                   |
|--------------------------------|------------------|-----------------------------------------------|-----------------------------------|
| <b>Product name:</b>           | 2000mg tablets   |                                               |                                   |
| <b>Date of sampling:</b>       | Unknown          | <b>Identification sample:</b><br>(client)     | Batch: 1307<br>Exp. Date: 11-2022 |
| <b>Date of receipt sample:</b> | 19 November 2021 | <b>Identification sample:</b><br>(Brightlabs) | BL- 2021-5058                     |
| <b>Date start of analysis:</b> | 25 November 2021 |                                               |                                   |

| Cannabinoids    |         | Analytical method: HPLC-UV |               |
|-----------------|---------|----------------------------|---------------|
| Compound        | Results | Unit                       | Specification |
| CBDVA           | <LOQ    | % (w/w)                    | Informative   |
| CBDV            | 0.02    | % (w/w)                    | Informative   |
| CBDa            | <LOQ    | % (w/w)                    | Informative   |
| CBGA            | <LOQ    | % (w/w)                    | Informative   |
| CBG             | <LOQ    | % (w/w)                    | Informative   |
| CBD             | 9.58    | % (w/w)                    | Informative   |
| THCV            | <LOQ    | % (w/w)                    | Informative   |
| CBN             | <LOQ    | % (w/w)                    | Informative   |
| CBCVA           | <LOQ    | % (w/w)                    | Informative   |
| $\Delta^9$ -THC | <LOQ    | % (w/w)                    | Informative   |
| $\Delta^8$ -THC | <LOQ    | % (w/w)                    | Informative   |
| CBL             | <LOQ    | % (w/w)                    | Informative   |
| CBC             | <LOQ    | % (w/w)                    | Informative   |
| THCA            | <LOQ    | % (w/w)                    | Informative   |
| CBCA            | <LOQ    | % (w/w)                    | Informative   |
| CBLA            | <LOQ    | % (w/w)                    | Informative   |
| CBT             | <LOQ    | % (w/w)                    | Informative   |

Limit of Quantification (LOQ): 0.005 % w/w

**Remarks:**

n/a

S. Hutjens  
Project Leader

FR112 EN R04